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Protective immunity against Toxoplasma gondii is mediated by the host cellular immune response.
Interleukin-12 (IL-12), a recently described cytokine that stimulates NK cells to produce gamma interferon
(IFN-y), is able to enhance host protection against this parasite in SCID mice. Administration of IL-12 to A/J
mice significantly increased survival over that of control mice when IL-12 was delivered early in the course of
acute infection. If it was administered at day 3 or thereafter, there was no observed difference in mortality
between treated and control mice. Antibody depletion of IL-12 increased susceptibility to infection, as
measured by mortality, only when the IL-12 was administered before day 3 postinfection. Mice treated with
IL-12 at day 0 postinfection exhibited a significant rise above the control in both IL-2 and IFN--y production.
Once infection has been established in the host (3 days), administration of exogenous IL-12 is unable to alter
parasite-induced downregulation of IFN--y production. Thus, IL-12 appears to play an important, but
transitory, role in protection against acute infection with T. gondii in the normal murine host.
Cell-mediated immunity is critical in host resistance to
infection with the obligate intracellular protozoan Toxoplasma
gondii (11). Both the CD4+ and, in particular, CD8+ T-cell
responses are involved in resolution of infection (1, 7, 14, 17).
However, NK cells appear to play a critical role in the response
to acute infection (16). These NK cells produce interferon
gamma (IFN-y), which in turn activates macrophages into a
microbicidal state. Recent studies in SCID mice show that
interleukin-12 (IL-12), a heterodimeric cytokine, is essential
for stimulation of NK cell IFN--y production and that macro-
phages appear to be an important source of this cytokine (8).
Furthermore, exogenous IL-12 is able to extend the life of
SCID mice infected with T. gondii cysts. In this report, we show
that exogenous IL-12 is able to enhance protection in normal
mice against acute T gondii infection only when administered
at the time of parasite challenge. Similarly, antibody directed
at IL-12 increases host susceptibility only when administered
shortly after infection.
MATERIALS AND METHODS
Animals and infection. Female A/J mice (Jackson Labora-
tory, Bar Harbor, Maine) were infected intraperitoneally with
either 104 (50% lethal dose [LD5J) or 5 x 104 (LD9,) P-strain
tachyzoites. Parasites used in these studies were obtained from
tissue culture in human fibroblast cells and were <50th
passage.
In vivo IL-12 treatment. Infected mice treated with the LD90
of P-strain parasites were given 0.33 pLg of recombinant murine
(rm) IL-12 (kindly supplied by Genetics Institute, Cambridge,
Mass.) in 0.2 ml of saline via daily intraperitoneal injection
beginning on day 0, 3, or 6 postinfection. Mice were observed
daily for evidence of infection (ruffled fur, weight loss, and
lethargy), and mortality was used as the endpoint. Control
mice were treated with an equal volume of saline.
In vivo depletion studies. For IL-12 depletion, mice were
treated intraperitoneally with 200 jig of rabbit anti-IL-12
antibody (kindly supplied by Genetics Institute) beginning on
* Corresponding author. Mailing address: Department of Microbi-
ology, Dartmouth Medical School, Hanover, NH 03755.
day 0 or 3 postinfection with the LD50 of parasites. Antibody
treatment was continued on an alternate-day basis for 14 days.
Control mice were treated with either a similar quantity of
normal rabbit immunoglobulin G (Sigma Chemical Co., St.
Louis, Mo.) or an equal volume of saline for the same period.
For IFN-y depletion, mice were treated with 3 mg of rat
anti-mouse IFN--y antibody (XMG6; American Type Culture
Collection) weekly. Control mice were given an equal quantity
of rat immunoglobulin G (Sigma). Depletion of NK cells was
accomplished by administering 50 ,ul of anti-asialo GM 1
antibody (Wako Chemicals) on alternate days throughout the
experiment. The antibody treatment was started 2 days prior to
parasite challenge.
Phenotypic analysis. Splenocytes were analyzed for T-cell
phenotype by a fluorescence-activated cell sorter (FACS;
Ortho Diagnostics), using direct immunofluorescence. Cells
(10') were incubated with 1 p.g of fluorescein isothiocyanate-
labelled anti-CD4 or anti-CD8 monoclonal antibody (MAb)
(PharMingen, San Diego, Calif.) or a 1:80 dilution of anti-
asialo GMI antibody (Wako Chemicals). After 45 min of
incubation at 37°C, the cells were washed with cold 3% bovine
serum albumin in phosphate-buffered saline (PBS), fixed with
2% paraformaldehyde in PBS, and analyzed by FACS scan
(Beckton Dickinson).
Assay for IL-2 and IFN-y production. Infected mice treated
with IL-12 or saline were splenectomized, and after homoge-
nization of the tissue, the erythrocytes were lysed by hypotonic
shock with 0.2% ammonium chloride. The cells were washed
and cultured at a concentration of 10" in Iscove medium (LTI,
Gaithersburg, Md.) with 10% fetal calf serum (Hyclone Lab-
oratories, Logan, Utah) in 24-well plates. Wells were stimu-
lated with 0.3 jig of whole parasite extract per ml prepared by
repeat freeze-thaw (four times). The lysed parasites were
centrifuged at 600 x g, and the soluble fraction was filtered.
The protein concentration was determined by the Bradford
method (Bio-Rad Laboratories, Richmond, Calif.). For IL-2
assay, cell culture supernatant was collected by centrifugation
after 24 h and stored at - 70°C until used. IL-2 analysis was
performed in a CTTL assay (5). To determine IFN-y produc-
tion, supernatants from cultured splenocytes were collected at
the completion of 48 h of incubation and stored as described
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FIG. 1. Depletion of IL-12 by antibody in mice following acute
infection with T. gondii. Inbred A/J mice (n = 6 to 10) were infected via
the intraperitoneal route with 104 P-strain tachyzoites (LD50). Mice
were treated with rabbit anti-IL-12 antibody (200 jig) on alternate days
beginning on either day 0 (A) or 3 (E) postinfection (P.I.). An equal
quantity of either normal rabbit antibody (0) or saline (K) was
similarly administered. Antibody therapy was continued through day
14, when the experiment was terminated. Results represent combined
data from two experiments.
above. IFN-y titers were assayed by enzyme-linked immu-
nosorbent assay (Endogen Inc., Boston, Mass.).
Detection of cytokine mRNA. Total cellular RNA was ex-
tracted from the splenocytes of mice by the guanidinium
thiocyanate method, as described previously (4). Total RNA
(10 jig) was fractionated in a 1.2% agarose-formaldehyde gel
and transferred to a nylon membrane (Hybond-N+; Amer-
sham, Arlington Heights, Ill.) with 0.05 M NaOH by capillary
transfer for 2 h. The membrane was prehybridized in 5 x SSPE
(1 x SSPE is 0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA
[pH 7.4])-0.5% sodium dodecyl sulfate (SDS)-5 x Denhardt
solution-20 ,ug of salmon sperm DNA per ml at 65°C for 1 h.
The filter was hybridized separately with cDNA probes for
murine IFN-,y (kindly supplied by Kevin Moore, Genentech,
San Francisco, Calif.) and human t-actin (Clontech, Palo Alto,
Calif.). Probe was labelled with [ct-32P]dATP to a specific
activity of > 109 cpm/,ug by a random-primer labelling method
(Boehringer, Mannheim, Germany). The filter was washed
twice with 2 x SSPE-0.1% SDS for 10 min at room tempera-
ture, twice with 2 x SSPE-0.1% SDS, and finally with 0.1 x
SSPE-0.1% SDS at 52°C for 10 min. Autoradiography was
performed at - 70°C for 24 h.
Statistical analysis. Student's t test was used for the analysis
of data in these experiments.
RESULTS
Antibody directed at IL-12 was used to determine whether
this cytokine was important in eliciting a protective response in
normal mice against acute T. gondii infection. Mice were
depleted of IL-12 with antibody on alternate days following
intraperitoneal infection. As shown in Fig. 1, all mice treated
with anti-IL-12 antisera on day 0 postchallenge died from T.
gondii infection by day 6 compared with control mice receiving
either nonspecific antibody or saline. The time postchallenge
at which administration of anti-IL-12 altered the host response
was crucial. If delivered shortly after infection and continued
on an alternate-day schedule, the antibody had a significant
effect in blocking host protective immunity (P < 0.01). If,
however, the antibody was delivered beginning on day 3
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FIG. 2. Effect of exogenous IL-12 on survival of mice following
acute infection with T. gondii. Inbred A/J mice (n = 6 to 10 per group)
were acutely infected via the intraperitoneal route with 5 x 104
P-strain tachyzoites (LD9t)). Following infection, mice were treated on
alternate days with exogenous rmIL-12 (0.33 jig) beginning on either
day 0 (A), 3 ([), or 6 (x). Control mice were treated with saline
beginning on day 0 (0). Treatment was continued through day 14 and
terminated. Results represent combined data from two experiments.
P.I., postinfection.
postinfection and on alternate days thereafter, there was no
significant difference in survival between the IL-12-depleted
mice and control mice that were treated with saline beginning
on day 0.
The ability of exogenous IL-12 to enhance protection in
normal mice was then evaluated by administration of this
cytokine to acutely infected mice. To perform this experiment,
mice were infected and administered rmIL-12 beginning either
immediately postinfection (day 0) or on day 3 or 6 postinfec-
tion, and administration was continued on a daily basis there-
after. As shown in Fig. 2, those mice receiving IL-12 on day 0
postinfection survived (87.5% survival), whereas all mice re-
ceiving IL-12 starting on day 3 or 6 postinfection died by day 8
or 9 (P < 0.001).
Splenocytes were phenotyped by FACS analysis for the
expression of either CD4+, CD8+, or NK cells. As shown in
Table 1, mice receiving IL-12 on day 0 exhibited a substantial
rise in their NK cell population (9.8%) compared with mice
receiving their first dose of IL-12 on day 3 (4.5%) or no IL-12
(2.3%). During this period, there was a small drop in the
number of cells expressing CD4+ but no change in the CD8+
count.
TABLE 1. Phenotypic analysis of T-cell subsets in mice acutely
infected with T. gondii and treated with rmIL-12a
Change (%) in given cell population
Treatment
CD4+ CD8+ NK
IL-12
Day 0 20.8 13.6 9.8
Day 3 18.6 15.3 4.5
Saline control 15.7 12.6 2.3
a Inbred A/J mice were infected with an LD9() of P-strain tachyzoites via
intrapertioneal inoculation. Alternate-day treatment with rmlL-12 began on day
0 or 3 postinfection. Mice were sacrificed on day 5 postinfection, and splenocytes
were evaluated for T-cell phenotype expression by FACS analysis after fluores-
cein isothiocyanate incubation. Results represent the averages of three mice per
group.
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TABLE 2. Analysis of cytokine production in mice acutely infected
with T. gondii and treated with rmIL-12a
IL-2 (pM) IFN-y (U/ml)
Treatment
Control +Tg Control +Tg
IL-12
Day 0 50 200 200 400
Day 3 <5 <5 50 100
Saline control <5 <5 <5 50
a Inbred A/J mice were infected with an LD9, of P-strain tachyzoites via
intraperitoneal inoculation. Alternate-day treatment with rmIL-12 began on day
O or 3 postinfection. Mice were sacrificed on day 5 postinfection, and splenocytes
were isolated and cultured in vitro in the presence of T. gondii parasite extract
(+Tg). After 24 h for IL-2 and 48 h for IFN-y, levels of these cytokines were
determined by biologic analysis.
Splenocytes from mice treated with exogenous IL-12 were
assayed for the production of both IL-2 and IFN-y. As shown
in Table 2, mice receiving IL-12 beginning on day 0 and on
alternate days thereafter had detectable levels of IL-2 on day 5
when splenocytes were incubated in both the presence and the
absence of parasite antigen. Significantly greater quantities of
IL-2 were produced by splenocytes incubated in the presence
of parasite antigen. Splenocytes obtained from mice that had
IL-12 therapy initiated on day 3 postinfection failed to produce
detectable quantities of IL-2 in culture as determined by our
assay. Similarly, control mice not treated with IL-12 failed to
produce IL-2 in both the presence and the absence of parasite
antigen. Both parasite antigen-stimulated and unstimulated
splenocytes from mice receiving IL-12 on day 0 postinfection
showed significant rises in levels of IFN-y. In comparison, mice
receiving IL-12 on day 3 postinfection had an observed, but
lesser, rise in IFN--y levels.
To further delineate the requirement for NK cells and IFN--y
in this model, IL-12-treated mice were MAb depleted of either
NK cells or IFN-,y. As shown in Fig. 3, depletion of IFN-,y
resulted in a significant increase in mortality, with all mice
dying by day 5 postinfection. Similarly, treatment with antibody
to NK cells resulted in all mice succumbing to infection by day
8. Control mice treated with IL-12 and a nonspecific immuno-
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FIG. 3. Antibody depletion of IFN-y and NK cells with MAb.
Three groups of mice (n = 6) were treated with either 3 mg of
anti-IFN-y (XMG6) (x), 50 ,ul of anti-asialo GM1 antibody (0), or an
equal amount (3 mg) of irrelevant immunoglobulin G (A). The
antibody treatment was started 2 days prior to administration of daily
IL-12 therapy (0.33 ,ug per mouse) and challenge with an LD90 of
parasites. P.I., postinfection.
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FIG. 4. Quantitative cytokine (IFN--y) mRNA analysis following
acute infection with T. gondii and treatment with rmIL-12. Inbred A/J
mice were challenged with an LD90 of P-strain tachyzoites via intra-
peritoneal inoculation and were treated with rmIL-12 daily. Mice that
were treated (n = 3 per group) with IL-12 beginning on day 0 (lane 1)
or 3 (lane 2) or with saline (lane 4) were sacrificed on day 5
postinfection. Another group of mice (n = 3) that were infected with
T. gondii and treated with IL-12 beginning on day 3 were sacrificed on
day 8 (lane 3). This allowed mice in both day 0 and 3 groups to receive
equal quantities of rmIL-12 prior to sacrifice. The cellular RNA from
the spleen cells was extracted, and message for IFN--y (a) and a ,-actin
control (b) was determined by Northern blot analysis.
globulin G exhibited significantly greater survival postinfec-
tion.
Quantitative expression of cytokine message was evaluated
by Northern (RNA) blot. For this experiment, mice were
infected on day 0 and treatment with IL-12 was initiated on
either day 0 or 3. Exogenous IL-12 was administered on a daily
basis once therapy began. Mice infected on day 0 and treated
with IL-12 on day 0 were sacrificed on day 5. Mice infected on
day 0 and not treated with IL-12 until day 3 were sacrificed on
either day 5 or 8. This allowed mice to receive equal quantities
of exogenous IL-12 prior to evaluation for cytokine message
expression. As shown in Fig. 4, splenocytes obtained from mice
receiving IL-12 at the time of infection (day 0) expressed a
substantial increase in the message for IFN--y at the time of
assay. For the mice that were infected but were not adminis-
tered IL-12 until day 3, there was no difference in the quantity
of expressed message for IFN--y.
DISCUSSION
Our observations indicate that IL-12 is an important medi-
ator of host defense during the acute phase of T gondii
infection in normal inbred mice. Administration of recombi-
nant IL-12 to normal mice on day 0 postinfection significantly
decreases morbidity and prolongs life against acute infection.
These findings confirm the recent observations of Gazzinelli et
al. (8), who observed marked prolongation of life in SCID mice
following administration of IL-12. However, in normal mice, it
appears that the effect of exogenous IL-12 occurs only at the
onset of infection. Thereafter (by day 3 postinfection), the
beneficial effect of this cytokine is no longer apparent, as
determined by mortality. Similarly, antibody to IL-12 blocks
the protective effect of this cytokine when administered on the
day of infection but not thereafter.
The mechanism by which IL-12 increases host protection
against T gondii infection appears to be the induction of NK
cells. Depletion of these cells in mice treated with IL-12
reverses the protective effect of this cytokine (Fig. 3). It would
appear that the NK cells produce greater quantities of IFN--y,
enhancing the microbicidal activity of macrophage (3). Addi-
tionally, IL-12 can augment the helper T-cell response to
produce more IL-2 (18). In our studies, we have observed a rise
in both IL-2 and IFN--y in the supernatants of cultured
splenocytes following administration of IL-12 to the host on
day 0 postinfection. We did not, however, observe a rise in the
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number of splenocytes expressing the CD4+ T-cell phenotype.
This is perhaps due to the involvement of immune organs (i.e.,
lymph nodes and intestinal epithelial cells) other than the
spleen. Our results do show a significant rise in the NK cell
population following administration of IL-12, in particular,
when the IL-12 is delivered on day 0. The NK cell response
observed on day 3 (4.5%) may not reflect the peak NK cell
response since we harvested splenocytes and measured for cell
phenotype at day 5 in both conditions (IL-12 administered on
days 0 and 3).
In these studies, administration of exogenous IL-12 at the
time of infection resulted in an increase of both IL-2 and
IFN-,y levels. Depletion of IFN--y with MAb reversed the
protective effect of the IL-12. However, delayed administration
(day 3) of exogenous IL-12 failed to augment the levels of IL-2
and IFN-y in the infected mice. There is abundant evidence for
defects in cellular immunity during T. gondii infection. De-
pressed lymphocyte proliferation to parasite antigens has been
observed in infants with congenital toxoplasmosis and in adults
with acute toxoplasmosis (2, 15). Generalized immunosuppres-
sion also occurs in mice infected with T. gondii (18, 21).
Preliminary results from our laboratory demonstrate that
decreased IL-2 production can be detected in the culture
supernatant of splenocytes derived from mice acutely infected
with T gondii and stimulated in vitro with mitogen (9). Both
macrophages and T cells from acutely infected mice produce a
soluble factor that is able to inhibit the proliferative response
of naive T cells to mitogen. The same culture supernatants
contain increased levels of IL-10, and partial neutralization of
the immunosuppressed condition can be observed following
administration of anti-IL-10 antibody (13). Since IL-10 is a
potent antagonist of the effects of IFN-y, it may be important
in mediating the immunosuppression observed. Recent studies
by D'Andrea et al. (6) suggest that IL-10 is able to inhibit the
production of IFN-y by suppressing IL-12 synthesis in acces-
sory cells. Perhaps the host primary response to T. gondii
involves the production of macrophage-derived IL-12, which in
turn stimulates the proliferation of NK cells and IFN-,y. Once
acute infection has been established, the parasite stimulates
the production of IL-10 in the host, which in turn inhibits IL-12
production and reduces IFN--y and IL-2 levels.
Our results indicate that the time of IL-12 administration is
critical for its ability to alter host infection. If IL-12 is
administered shortly after infection, it is able to significantly
enhance protection against acute toxoplasma infection. If,
however, this cytokine is administered on day 3 or later
postinfection, the ability to enhance the protective response is
lost. This reduced protective response is perhaps due to the
parasite having established itself within the host, making the
role of NK cell-mediated protection less important. This
confirms earlier studies of Hughes et al. (10), who demon-
strated that although NK cells are present beyond day 3 of
infection, they do not appear to be important in modulating
host protection against infection. Previous studies from our
laboratory (12) and by others (17) indicate that, beyond day 3,
the host CD8+ T-cell response in association with the produc-
tion of high-titer IFN-,y is necessary for host survival. Thus, the
role of IL-12 may be transitory and important only in modu-
lating the host immune response to the initial phase of acute
primary infection.
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